CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma

Immune checkpoint inhibitors (ICIs) resistance limits immunotherapy success in hepatocellular carcinoma (HCC). However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in HCC against anti-PD-1 therapy.

Source: Journal of Hepatology - February 22, 2024 Category: Gastroenterology Authors: Peiyi Xie, Mincheng Yu, Bo Zhang, Qiang Yu, Yufei Zhao, Mengyuan Wu, Lei Jin, Jiuliang Yan, Binghai Zhou, Shuang Liu, Xiaoqiang Li, Chenhao Zhou, Xiaodong Zhu, Cheng Huang, Yongfeng Xu, Yongsheng Xiao, Jian Zhou, Jia Fan, Mien-Chie Hung, Qinghai Ye, Lei G Tags: Research Article Source Type: research